Stryker Corporation $SYK Shares Acquired by Ashton Thomas Private Wealth LLC

Key Points

• Ashton Thomas Private Wealth LLC increased its stake in Stryker Corporation by 23.8% during the 1st quarter, owning a total of 21,252 shares valued at approximately $7.93 million.
• Insider Ronda E. Stryker sold 200,000 shares of stock for about $75.29 million, resulting in a 5.84% decrease in their position.
• Stryker recently reported earnings of $3.13 EPS, surpassing analysts' expectations and projecting annual earnings per share guidance of $13.400-13.600 for FY 2025.

Ashton Thomas Private Wealth LLC increased its stake in Stryker Corporation (NYSE:SYK - Free Report) by 23.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,252 shares of the medical technology company's stock after acquiring an additional 4,086 shares during the period. Ashton Thomas Private Wealth LLC's holdings in Stryker were worth $7,929,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Capital A Wealth Management LLC acquired a new stake in shares of Stryker in the fourth quarter valued at $26,000. Goodman Advisory Group LLC acquired a new position in Stryker during the 1st quarter worth approximately $32,000. City Holding Co. grew its holdings in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after acquiring an additional 74 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Stryker during the 1st quarter worth $40,000. Finally, IMA Advisory Services Inc. purchased a new stake in shares of Stryker during the 1st quarter worth $46,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Truist Financial set a $415.00 price objective on shares of Stryker and gave the stock a "hold" rating in a research report on Monday, August 4th. Evercore ISI lifted their price objective on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Citigroup reaffirmed a "buy" rating and set a $455.00 price objective (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Wells Fargo & Company lifted their price objective on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $430.10.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Stryker Trading Down 0.6%

Shares of Stryker stock opened at $392.02 on Monday. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company has a market capitalization of $149.87 billion, a P/E ratio of 51.92, a PEG ratio of 2.85 and a beta of 0.93. The company's fifty day moving average is $389.52 and its two-hundred day moving average is $379.51.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. During the same quarter last year, the business earned $2.81 EPS. The business's revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.